iBio's Fiscal Year 2024: Innovations and Financial Insights
Overview of iBio’s Fiscal Year 2024 Financial Results iBio, Inc. (NYSEA:IBIO), a leader in biopharmaceuticals using AI technology, has recently shared its financial performance for the fiscal year that ended on June 30, 2024. The company is dedicated to developing antibody therapies for complex conditions, utilizing machine learning approaches to enhance their efforts....
Continue Reading